SCHEMBL182970

SCHEMBL182970

COc1ccc(-c2ccc3[nH]c(=O)[nH]c(=O)c3c2)cc1OC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.64
ALDH1A1 P00352 2/20 0.64
HPGD P15428 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
PDE4A P27815 3/20 0.49
PDE4B Q07343 3/20 0.49
PDE4C Q08493 3/20 0.49
PDE4D Q08499 3/20 0.49
GUSB P08236 1/20 0.49
MCL1 Q07820 1/20 0.48
TLR7 Q9NYK1 5/20 0.47
TLR8 Q9NR97 4/20 0.47
TLR9 Q9NR96 3/20 0.47
MAPT P10636 1/20 0.45
THRB P10828 1/20 0.45
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
GRIA1 P42261 1/20 0.44
CACNG8 Q8WXS5 1/20 0.44
TERT O14746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2895978 0.79 KDM4E (1.00) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL3920785 0.76 KDM4E (0.58) KDM4EALDH1A1HPGDSMN1; SMN2PDE4A
SCHEMBL8900615 0.76 PDE3A (0.62) KDM4EALDH1A1HPGDSMN1; SMN2CA12
SCHEMBL3124589 0.76 ALDH1A1 (0.63) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL31441277 0.74 CA12 (0.49) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL18020129 0.74 PARP1 (0.61) KDM4EALDH1A1HPGDSMN1; SMN2CA12
SCHEMBL17979420 0.74 CA12 (0.49) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL10567524 0.74 ALDH1A1 (0.62) KDM4EALDH1A1HPGDSMN1; SMN2PDE4A
SCHEMBL18020134 0.73 PDE3A (0.59) KDM4EALDH1A1HPGDSMN1; SMN2CA12
SCHEMBL8840880 0.72 PDE4A (0.67) KDM4EALDH1A1HPGDSMN1; SMN2PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 EP disclosed
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 EP disclosed
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors NOVARTIS AG 2009-10-15 US disclosed
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors NOVARTIS AG 2009-10-15 US disclosed
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors NOVARTIS AG 2009-10-15 US disclosed
EP-2049502-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2009-04-22 EP disclosed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 WO disclosed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors PDPK1, PI4KA, PIK3CA KDM4E 1674/4885ALDH1A1 1849/4885HPGD 1007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.